|
1
|
Zhang LY, Cai SJ, Liang BY, Yan SY, Wang B, Li MY, Zhao WX. Efficacy of anlotinib combined with radioiodine to treat scalp metastasis of papillary thyroid cancer: A case report and review of literature. World J Clin Cases 2023; 11:2839-2847. [PMID: 37214573 PMCID: PMC10198115 DOI: 10.12998/wjcc.v11.i12.2839] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/30/2022] [Revised: 02/27/2023] [Accepted: 03/22/2023] [Indexed: 04/25/2023] Open
Abstract
BACKGROUND Papillary thyroid cancer (PTC) is one of the well-differentiated thyroid tumors. Cutaneous metastasis from differentiated thyroid cancers occurs in < 1% of primary thyroid carcinomas but produces the worst survival prognosis. The multi-targeting tyrosine kinase inhibitor anlotinib has been approved to treat refractory advanced non-small-cell lung cancer as well as advanced soft-tissue and clear cell sarcomas in China. CASE SUMMARY In a patient with scalp metastasis caused by PTC, thyroid and skull metastasis tumor sizes were significantly reduced after a trial of neoadjuvant anlotinib therapy for 3 cycles. Anlotinib maintenance medication after thyroidectomy further reduced the metastatic skull tumor size thereby preventing the requirement for craniotomy. CONCLUSION The outcome of the present trial confirmed the potential of anlotinib therapy to treat scalp metastasis induced by PTC and point the way for the treatment of similar diseases in the future.
Collapse
Affiliation(s)
- Li-Yong Zhang
- Department of Thyroid Surgery, General Surgery, Minimal Invasive Center, The Training Center for Intraoperative Neurophysiologic Monitoring of Thyroid and Parathyroid, Fujian Medical University Union Hospital, Fujian Medical University, Fuzhou 350001, Fujian Province, China
| | - Shao-Jun Cai
- Department of Thyroid Surgery, General Surgery, Minimal Invasive Center, The Training Center for Intraoperative Neurophysiologic Monitoring of Thyroid and Parathyroid, Fujian Medical University Union Hospital, Fujian Medical University, Fuzhou 350001, Fujian Province, China
| | - Bo-Yan Liang
- Department of Thyroid Surgery, General Surgery, Minimal Invasive Center, The Training Center for Intraoperative Neurophysiologic Monitoring of Thyroid and Parathyroid, Fujian Medical University Union Hospital, Fujian Medical University, Fuzhou 350001, Fujian Province, China
| | - Shou-Yi Yan
- Department of Thyroid Surgery, General Surgery, Minimal Invasive Center, The Training Center for Intraoperative Neurophysiologic Monitoring of Thyroid and Parathyroid, Fujian Medical University Union Hospital, Fujian Medical University, Fuzhou 350001, Fujian Province, China
| | - Bo Wang
- Department of Thyroid Surgery, General Surgery, Minimal Invasive Center, The Training Center for Intraoperative Neurophysiologic Monitoring of Thyroid and Parathyroid, Fujian Medical University Union Hospital, Fujian Medical University, Fuzhou 350001, Fujian Province, China
| | - Meng-Yao Li
- Department of Thyroid Surgery, General Surgery, Minimal Invasive Center, The Training Center for Intraoperative Neurophysiologic Monitoring of Thyroid and Parathyroid, Fujian Medical University Union Hospital, Fujian Medical University, Fuzhou 350001, Fujian Province, China
| | - Wen-Xin Zhao
- Department of Thyroid Surgery, General Surgery, Minimal Invasive Center, The Training Center for Intraoperative Neurophysiologic Monitoring of Thyroid and Parathyroid, Fujian Medical University Union Hospital, Fujian Medical University, Fuzhou 350001, Fujian Province, China
| |
Collapse
|
|
2
|
Zhu J, Chen DS, Ma YJ, Chen ML, Yang Y. Next-generation sequencing reveals tumour origin in a patient with rare metachronous colonic metastasis from pancreatic cancer. Eur J Cancer 2022; 163:77-78. [PMID: 35033995 DOI: 10.1016/j.ejca.2021.12.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2021] [Accepted: 12/16/2021] [Indexed: 11/30/2022]
Affiliation(s)
- Jing Zhu
- Department of Oncology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, 211100, China
| | - Dong-Sheng Chen
- The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, 211100, China; The State Key Laboratory of Translational Medicine and Innovative Drug Development, Nanjing, 210002, China
| | - Ya-Jun Ma
- Department of Oncology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, 211100, China
| | - Mei-Li Chen
- Department of Oncology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, 211100, China
| | - Yan Yang
- Department of Oncology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, 211100, China.
| |
Collapse
|